Loading...
Market
Market share outcomes for PNH and aHUS treatments by end of 2024
4
Resolution / Starting Odds
Amgen's Bkemv dominates • 33%
AstraZeneca retains majority market share • 33%
Other competitors gain significant market share • 34%
Market research reports or analysis from credible healthcare research firms
Story
FDA Approves Amgen's Interchangeable Biosimilar to AstraZeneca's Soliris on Tuesday
May 28, 2024, 10:30 PM
The U.S. Food and Drug Administration (FDA) has approved Amgen's Bkemv, the first interchangeable biosimilar to AstraZeneca's Soliris, a treatment for rare blood disorders. Bkemv is approved for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis and atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. This approval, announced on Tuesday, marks a significant milestone in the availability of biosimilar treatments for rare diseases.
View original story
Similar markets
Dominant new treatment • 25%
Widely used alongside others • 25%
Limited use • 25%
Rarely used • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Moderna gains highest market share • 33%
Pfizer retains highest market share • 33%
BioNTech gains highest market share • 33%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
Ozempic gains over 30% market share • 25%
Ozempic gains 10-30% market share • 25%
Ozempic gains less than 10% market share • 25%
Ozempic loses market share • 25%
Decrease by more than 10% • 25%
Decrease by less than 10% • 25%
Remain stable • 25%
Increase • 25%
Viking Therapeutics • 33%
Madrigal Pharmaceuticals • 33%
GPCR • 33%
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
Market position strengthened • 33%
Market position weakened • 33%
Market position remains stable • 34%
<20% • 25%
20%-40% • 25%
40%-60% • 25%
>60% • 25%
Donanemab surpasses Leqembi in market share • 33%
Donanemab equals Leqembi in market share • 33%
Leqembi remains ahead in market share • 33%